title: Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
abstract: OBJECTIVE
  To evaluate stimulant medication on symptoms and functioning for college students with ADHD using double-blind, placebo-controlled, crossover design.
  
  
  METHODS
  Participants included 24 college students with ADHD and 26 college students without psychopathology. Lisdexamfetamine dimesylate (LDX) was examined for ADHD participants over five weekly phases (no-drug baseline, placebo, 30-, 50-, and 70-mg LDX per day). Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side effects were collected (baseline only for control students).
  
  
  RESULTS
  LDX was associated with large reductions in ADHD symptoms and improvement in executive functioning along with smaller effects for psychosocial functioning. Reduction in ADHD symptoms was found for 86.4% of participants; however, large differences in symptoms and executive functioning remained relative to controls.
  
  
  CONCLUSIONS
  LDX is a safe, efficacious treatment for symptom relief in college students with ADHD. Research documenting medication effects on academic functioning and evaluating psychosocial/educational interventions is needed.
authors.affiliation: Lehigh University, Bethlehem, PA 18015, USA. gjd3@lehigh.edu
authors.forename: George J
authors.initials: GJ
authors.lastname: Dupaul
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Weyandt
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Rossi
authors.forename: Brigid A
authors.initials: BA
authors.lastname: Vilardo
authors.forename: Sean M
authors.initials: SM
authors.lastname: O'Dell
authors.forename: Kristen M
authors.initials: KM
authors.lastname: Carson
authors.forename: Genevieve
authors.initials: G
authors.lastname: Verdi
authors.forename: Anthony
authors.initials: A
authors.lastname: Swentosky
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003913:Dextroamphetamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D056344:Executive Function / Q000187:drug effects; D005260:Female; D006801:Humans; D007858:Learning / Q000187:drug effects; D000069478:Lisdexamfetamine Dimesylate; D008297:Male; D009483:Neuropsychological Tests; D013334:Students / Q000523:psychology*; D016896:Treatment Outcome; D014495:Universities; D055815:Young Adult
chemical_list: D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine